In this data-driven and clinically rich presentation, Dr. Pornchai O-Charoenrat shares two compelling breast cancer cases that demonstrate how ctDNA-based minimal residual disease (MRD) testing can transform patient management. Through the K-TRACK™ assay, he highlights its value in detecting occult disease invisible to imaging, guiding complex treatment decisions, and tracking molecular responses well before clinical or radiologic changes appear.
The first case features a 90-year-old with HER2-enriched locally advanced breast cancer, where ctDNA clearance during neoadjuvant therapy predicted a complete pathological response. The second presents a 42-year-old mother with recurrent luminal B/HER2+ disease, where a subtle ctDNA rise led to the discovery of early bone metastasis before symptoms or scan changes, enabling timely intervention.
Through these cases, Dr. Pornchai illustrates how ctDNA-MRD offers a sensitive, real-time biomarker for risk stratification, treatment monitoring, and early recurrence detection—adding a powerful layer of precision to oncology practice.
